German health reform row splits coalition; government could fall

1 October 2006

There is widespread agreement among German political commentators that the continuing and intensifying controversy over coalition health reform plans could bring down the government under Chancellor Angela Merkel.

The Christian Democrats (CDU) appear to have lost their enthusiasm for the reforms agreed with the Social Democrats (SPD) and greeted as recently as July this year as a "real breakthrough" by the Chancellor. Volker Kauder, head of the CDU in parliament, says that his party is committed to the program but other party activists want to make radical changes. Recriminations have already begun between CDU and SPD politicians.

The main focus of the row is the so-called "One Percent Rule," under which all health fund patients would pay a maximum of 1% of their household income to top up additional premium payments needed by the individual funds. CDU sources have said that, although this has been agreed by the coalition, experts are pointing to its impracticability.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight